About us
In brief
The Board of Directors
Management Team
Corporate Governance
Intellectual Properties
Partnerships
Environment & quality
Organization
Career
Project portfolio
Project overview
Research areas
Development phases
Publications
Contract research
Autoradiography
Pharmacokinetics
Analytical chemistry
Disease models
Investor info
Contacts
Press releases
Stock
Interim reports
Annual reports
Presentations
Ownership
Official documents
Calendar
Press & news
Press releases
Interim reports
Annual reports
Features
Image bank
Calendar
Contacts
Contact
Visit us
RSS
font size
Investor info
Contacts
Press releases
Subscribe
Stock
Interim reports
Annual reports
Presentations
Ownership
Official documents
Calendar
Press releases
In English
2013-05-16
New data to be presented at the 2013 ASCO Annual Meeting show Active Biotech's commitment to oncology research
2013-05-16
Annual General Meeting of Active Biotech AB
2013-04-25
Active Biotech AB Interim Report January - March 2013
2013-04-25
Active Biotech and Ipsen update the analysis plan for the 10TASQ10 trial evaluating tasquinimod in the treatment of prostate cancer
2013-04-15
Annual Report 2012 Active Biotech AB (publ)
2013-04-11
Active Biotech - Notice of Annual General Meeting of Shareholders
2013-03-28
Number of shares and votes in Active Biotech
2013-03-21
EARLY VERSUS DELAYED TREATMENT WITH LAQUINIMOD DEMONSTRATED SIGNIFICANT REDUCTION IN RISK OF DISABILITY PROGRESSION - RESULTS OF THREE-YEAR ALLEGRO STUDY IN RELAPSING-REMITTING MULTIPLE SCLEROSIS
2013-03-06
FIRST PATIENT ENROLLED IN THIRD PHASE III STUDY OF ORAL LAQUINIMOD FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS
2013-03-06
Active Biotech raises SEK 270 million through a directed new issue to Investor
2013-02-14
Active Biotech AB Year-end report January - December 2012
2013-01-28
Results from Active Biotech's Phase II/III ANYARA trial for the treatment of renal cell cancer
2013-01-03
Active Biotech to Present at the JP Morgan 31st Annual Healthcare Conference
2012-12-12
Laquinimod highlights from Teva Investor Day December 11
2012-12-11
Teva Investor Meeting December 11
2012-12-10
Active Biotech and Ipsen announce completion of recruitment of tasquinimod clinical phase III study in prostate cancer
2012-11-15
Active Biotech's election committee appointed
2012-11-09
Active Biotech AB Interim report January - September 2012
2012-10-22
PHASE IIa LAQUINIMOD TRIAL RESULTS SHOW POSITIVE DATA FOR POTENTIAL USE IN ACTIVE CROHN'S DISEASE
2012-10-19
Active Biotech's partner Ipsen initiates a proof-of-concept study with tasquinimod in additional cancer indications
2012-10-03
Ipsen initiates a phase II "Switch maintenance" trial in metastatic castrate-resistant prostate cancer with tasquinimod
2012-10-01
Tasquinimod Biomarker Phase II data presented at ESMO 2012
2012-09-06
Active Biotech to Present at the Rodman & Renshaw Annual Global Investment Conference
2012-08-10
Active Biotech AB Interim report January - June 2012
2012-08-08
TEVA TO INITIATE THIRD PHASE III TRIAL OF ORAL LAQUINIMOD FOR THE TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS
2012-07-17
ACTIVE BIOTECH ANNOUNCE THAT EUROPEAN MEDICINES AGENCY ACCEPTS START OF SCIENTIFIC REVIEW OF THE MARKETING AUTHORIZATION APPLICATION FOR LAQUINIMOD IN RELAPSING-REMITTING MULTIPLE SCLEROSIS
2012-06-04
Active Biotech's and Ipsen's Tasquinimod shows encouraging overall survival improvement in castrate resistant prostate cancer
2012-05-31
Active Biotech to Present at the Jefferies 2012 Global Healthcare Conference
2012-05-29
Active Biotech invites to Capital Markets Day
2012-05-21
600 Patients Recruited in Active Biotech's and Ipsen's tasquinimod Clinical Phase III Study
2012-05-18
Active Biotech and Ipsen to present Tasquinimod Phase II Overall Survival data at the 2012 ASCO Annual Meeting
2012-05-11
Annual General Meeting of Active Biotech AB
2012-04-26
Active Biotech AB Interim report January - March 2012
2012-04-17
Annual Report 2011 Active Biotech AB (publ)
2012-04-11
Active Biotech: Notice of Annual General Meeting of Shareholders
2012-03-15
Phase III Study of Teva's Oral Laquinimod Published in the New England Journal of Medicine Demonstrates Clinical Benefits for Multiple Sclerosis Patients
2012-02-24
Active Biotech and Ipsen report for the first time Tasquinimod (TASQ) phase II long term safety data at the 27th European Association of Urology (EAU) Congress
2012-02-16
Year-end Report January - December 2011
2012-01-23
Active Biotech's Prostate Cancer Project TASQ in Phase I Combination Therapy Trial
2012-01-04
Active Biotech to Present at the JP Morgan 30th Annual Healthcare Conference
2011-11-10
Active Biotech's election committee appointed
2011-11-03
Active Biotech AB Interim Report January - September 2011
2011-11-02
Information regarding Active Biotech's candidate drug laquinimod
2011-10-19
INVESTIGATIONAL LAQUINIMOD DEMONSTRATES ITS POTENTIAL AS A NEW ORAL TREATMENT FOR RRMS
2011-09-20
Active Biotech's Prostate Cancer Project TASQ Featured in Journal of Clinical Oncology
2011-08-11
Active Biotech AB Interim Report January - June 2011
2011-08-01
RESULTS OF PHASE III BRAVO TRIAL REINFORCE UNIQUE PROFILE OF LAQUINIMOD FOR MULTIPLE SCLEROSIS TREATMENT
2011-06-30
Number of shares and votes in Active Biotech
2011-06-08
Active Biotech to Present at the Jefferies 2011 Global Healthcare Conference
2011-05-31
Number of shares and votes in Active Biotech
2011-05-26
Active Biotech Presents Data regarding the 57-57 Project at EULAR
2011-05-06
Annual General Meeting of Active Biotech AB
2011-04-29
Number of shares and votes in Active Biotech
2011-04-28
Active Biotech AB Interim Report January - March 2011
2011-04-26
Active Biotech's partner Teva comments on DEFINE study results in Multiple Sclerosis
2011-04-18
Active Biotech and Ipsen enter into a broad partnership for the co-development and commercialization of TASQ in uro-oncology
2011-04-14
Active Biotech's nomination committee proposes election of an additional new board member
2011-04-12
ORAL LAQUINIMOD FOR MULTIPLE SCLEROSIS TREATMENT SIGNIFICANTLY REDUCED DISEASE ACTIVITY AND DISABILITY PROGRESSION WHILE PROVIDING GOOD SAFETY AND TOLERABILITY
2011-04-11
Teva Announces Webcast on Results from Phase III ALLEGRO Study of Oral Laquinimod in Multiple Sclerosis
2011-04-06
Annual Report 2010 Active Biotech AB (publ)
2011-04-05
Notice of Annual General Meeting of Shareholders
2011-03-15
Helén Tuvesson appointed as new Chief Scientific Officer at Active Biotech
2011-02-28
Number of shares and votes in Active Biotech
2011-02-18
Active Biotech's TASQ prostate cancer project presented at 2011 Genitourinary Cancers Symposium
2011-02-10
Active Biotech AB Year-end Report January - December 2010
2011-01-27
Active Biotech successfully completes private placement of SEK 375 million
2011-01-26
Active Biotech announces launch of private placement of new shares
2010-12-30
Number of shares and votes in Active Biotech
2010-12-09
TEVA ANNOUNCES SUCCESSFUL RESULTS OF PHASE III STUDY WITH ORAL LAQUINIMOD FOR MULTIPLE SCLEROSIS
2010-11-18
Orphan Medicinal Product Status to Active Biotech's 57-57 project recommended
2010-11-03
Active Biotech's election committee appointed
2010-10-29
Number of shares and votes in Active Biotech
2010-10-27
Active Biotech AB Interim Report January - September 2010
2010-10-15
NEW DATA EVALUATING LAQUINIMOD FOR THE TREATMENT OF MULTIPLE SCLEROSIS DEMONSTRATE NEUROPROTECTIVE EFFECTS
2010-09-30
Number of shares and votes in Active Biotech
2010-09-20
ORAL LAQUINIMOD DEMONSTRATED SUSTAINED EFFICACY AND SAFETY IN PATIENTS WITH MULTIPLE SCLEROSIS
2010-09-16
Active Biotech to Present at the UBS Global Life Sciences Conference
2010-09-09
Active Biotech to Present at the Rodman & Renshaw 12th Annual Healthcare Conference
2010-08-11
Active Biotech AB Interim report January - June 2010
2010-07-30
Number of shares and votes in Active Biotech
2010-06-30
Number of shares and votes in Active Biotech
2010-06-10
Active Biotech Capital Markets Day
2010-06-07
Active Biotech's TASQ prostate cancer project presented at ASCO
2010-05-21
Active Biotech's TASQ prostate cancer project to be presented at ASCO
2010-05-18
Active Biotech's Renal Cancer Project ANYARA Featured in Journal of Immunotherapy
2010-05-18
Active Biotech invites to Capital Markets Day
2010-05-17
Active Biotech's Prostate Cancer Project TASQ Featured in Molecular Cancer
2010-05-17
Active Biotech to Present at the Rodman & Renshaw 6th Annual Global Healthcare Conference
2010-05-07
Annual General Meeting of Active Biotech AB
2010-04-30
Number of shares and votes in Active Biotech
2010-04-22
Active Biotech AB Interim report January - March 2010
2010-04-20
Annual Report 2009 Active Biotech AB (publ)
2010-04-15
NEW DATA SUGGEST ORAL LAQUINIMOD MAY CONFER NEUROPROTECTION IN ADDITION TO IMMUNOMODULATION IN THE TREATMENT OF MULTIPLE SCLEROSIS
2010-04-06
Notice of Annual General Meeting of Shareholders
2010-04-01
Active Biotech raises SEK 149 million through a directed share issue
2010-03-31
Number of shares and votes in Active Biotech
2010-02-26
Number of shares and votes in Active Biotech
2010-02-11
Active Biotech AB Year-end Report, January - December 2009
2010-02-10
Exploratory data presented for Active Biotech's ANYARA project
2010-02-08
TEVA ACQUIRES MARKETING RIGHTS FOR ORAL LAQUINIMOD IN THE NORDIC AND BALTIC REGIONS
2009-12-14
Primary endpoint reached in Active Biotech's TASQ Phase II clinical trial in prostate cancer patients
2009-11-05
Active Biotech's election committee appointed
2009-11-05
Active Biotech AB Interim Report, January - September 2009
2009-10-05
RhuDex Clinical Development to Continue Following Feedback from Regulatory Authorities
2009-09-25
Active Biotech's Prostate Cancer Project TASQ Featured in British Journal of Cancer
2009-09-17
Active Biotech to Present at the UBS Global Life Sciences Conference
2009-09-11
LAQUINIMOD IMMUNOMODULATORY ACTION CONFERS BOTH NEUROPROTECTIVE AND ANTI-INFLAMMATORY PROPERTIES
2009-09-08
Laquinimod presentations at ECTRIMS
2009-09-04
Active Biotech to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
2009-08-07
New information regarding RhuDex(TM)
2009-08-06
Active Biotech AB Interim report January-June 2009
2009-07-28
Active Biotech's Cancer Project ANYARA Featured in Journal of Clinical Oncology
2009-06-30
Number of shares and votes in Active Biotech
2009-06-25
Teva Completes Enrollment in Second Oral Laquinimod Phase III MS Clinical Trial
2009-06-15
Active Biotech's rights issue substantially oversubscribed
2009-06-11
Active Biotech Presents Data regarding the 57-57 SLE Project at EULAR
2009-06-08
Active Biotech Completes Patient Enrollment to TASQ Clinical Phase II study
2009-06-01
Active Biotech Completes Patient Enrollment to ANYARA Phase III Clinical Trial
2009-05-18
Announcement of prospectus regarding rights issue in Active Biotech AB (publ)
2009-05-08
Annual General Meeting of Active Biotech AB
2009-04-28
NEW DATA ILLUSTRATE NOVEL MECHANISM OF ACTION OF LAQUINIMOD, AN ORAL COMPOUND FOR THE TREATMENT OF MULTIPLE SCLEROSIS
2009-04-28
Active Biotech presents S100A9 as a target for quinoline compounds
2009-04-23
Active Biotech AB Interim report January-March 2009
2009-04-06
Annual Report 2008 Active Biotech AB (publ)
2009-04-06
The Board of Active Biotech AB proposes that the Annual General Meeting resolve to make a guaranteed rights issue of approximately SEK 256 M
2009-04-06
Notice of Annual General Meeting of Shareholders
2009-02-12
ORAL LAQUINIMOD FOR MULTIPLE SCLEROSIS GRANTED FAST TRACK STATUS BY FDA
2009-02-12
Active Biotech AB year End Report January-December 2008
2009-01-26
Information from Active Biotech AB's Election Committee
2008-12-10
Active Biotech's Cancer Project ANYARA: Combination with Established Tumor Therapies Promising
2008-11-28
Active Biotech's election committee appointed
2008-11-18
Teva Completes Enrollment in Laquinimod Phase III Clinical Trial
2008-11-14
Active Biotech AB Interim Report January-September 2008
2008-11-06
Active Biotech to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
2008-10-28
Active Biotech Presents New Data regarding the 57-57 SLE Project at American College of Rheumatology Meeting
2008-10-17
New information regarding RhuDex®
2008-09-18
LAQUINIMOD DEMONSTRATED SIGNIFICANT AND SUSTAINED IMPACT ON MULTIPLE SCLEROSIS DISEASE ACTIVITY
2008-09-17
Active Biotech to Present at the UBS 2008 Global Life Sciences Conference
2008-08-06
Active Biotech AB Interim Report January-June 2008
2008-07-23
Tomas Leanderson appointed new President & CEO for Active Biotech
2008-07-16
TEVA ENROLLS PATIENTS FOR A SECOND LARGE GLOBAL PHASE III TRIAL OF ORAL LAQUINIMOD
2008-06-30
Number of shares and votes in Active Biotech
2008-06-24
RhuDex® Achieves Positive Results in Clinical Phase IIa Trial
2008-06-20
Active Biotech's Novel MS Compound laquinimod Featured in the Scientific Publication The Lancet
2008-06-12
Active Biotech's new issue fully subscribed
2008-05-15
Announcement of prospectus regarding rights issue in Active Biotech AB (publ)
2008-05-15
Active Biotech to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
2008-05-13
Active Biotech advances ANYARA into Phase III clinical trial
2008-05-08
Annual General Meeting of Active Biotech AB
2008-05-07
Annual Report 2007 Active Biotech AB (publ)
2008-04-24
Active Biotech AB Interim Report January-March 2008
2008-04-15
Preclinical data presented for Active Biotech's ANYARA technology
2008-04-09
Invitation to Annual General Meeting of Shareholders
2008-04-07
The Board of Active Biotech AB proposes that the Annual General Meeting resolve to make a guaranteed rights issue of approximately SEK 160 M
2008-02-14
Active Biotech Year-End Report January-December 2007
2007-11-22
Active Biotech's election committee appointed
2007-11-08
Active Biotech Interim Report Jan-Sep 2007
2007-11-07
Invitation Conference Call - Active Biotech AB
2007-11-07
INITIATION OF ENROLLMENT IN PIVOTAL PHASE III CLINICAL STUDY OF ORAL LAQUINIMOD FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS
2007-11-01
Active Biotech to Present at the Rodman & Renshaw 9th Annual Healthcare Conference
2007-10-24
Active Biotech's Cancer Project ANYARA Proven Safe in Combination with Taxotere®
2007-10-02
RhuDex®; MediGene Obtains US Patent
2007-09-20
Active Biotech to Present at the UBS 2007 Global Life Sciences Conference
2007-08-10
FDA Approves IND for Phase II Studies of TASQ
2007-08-09
Active Biotech Interim Report January-June 2007
2007-07-26
EMEA Grants Orphan Drug Status to Active Biotech's Cancer Treatment ANYARA
2007-06-18
Active Biotech presents new pre-clinical data for the 57-57 project at the 8th World Congress on Inflammation
2007-06-15
New positive pre-clinical data for Active Biotech's RA project I-3D
2007-06-07
TEVA AND ACTIVE BIOTECH TO INITIATE PIVOTAL PHASE III TRIAL PROGRAM OF ORAL LAQUINIMOD FOR RELAPSING MULTIPLE SCLEROSIS
2007-05-10
Active Biotech to Present at the Rodman & Renshaw 4th Annual Global Healthcare Conference
2007-05-04
Active Biotech Interim Report Jan-March 2007
2007-05-03
Active Biotech to Present at BIO 2007 Annual International Convention
2007-05-01
Laquinimod, a Novel Oral Compound, Showed Significant Reduction in Disease Activity in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS)
2007-04-20
Annual General Meeting of Active Biotech AB
2007-03-28
Early repayment of Active Biotech's convertible loan
2007-03-27
Active Biotech Publishes Data Regarding the TASQ Prostate Cancer Project
2007-03-22
Invitation to Annual General Meeting of Shareholders
2007-03-15
The Election Committee's proposal for approval by the Annual General Meeting of Active Biotech
2007-03-13
Active Biotech's I-3D micro-dosing clinical trial concluded
2007-03-09
Positive Clinical Data for TASQ - Active Biotech's Novel Treatment of Prostate Cancer
2007-02-15
Active Biotech calls for premature repayment of convertible loan
2007-02-15
Active Biotech Year-End Report 2006
2007-02-14
Active Biotech's new share issue oversubscribed
2007-01-23
RhuDex® Enters Clinical Phase IIa Trial in Rheumatoid Arthritis
2007-01-12
Active Biotech's nominations committee appointed
2007-01-04
Active Biotech's Guaranteed Preferential Rights Issue of SEK 240 M; Correction
2006-12-18
Active Biotech to conduct guaranteed preferential rights issue for approximately SEK 240 M
2006-12-13
Active Biotech's Novel Cancer Treatment ANYARA Shows Pharmacological Proof of Concept after Successful Phase I Studies
2006-11-21
Active Biotech receives 5 MSEK from VINNOVA
2006-11-02
Active Biotech Interim Report Jan-Sep 2006
2006-11-01
Active Biotech to Present at the Rodman & Renshaw 8th Annual Healthcare Conference
2006-10-09
Maria Borelius leaves the Board of Active Biotech AB
2006-09-20
Positive clinical results for Active Biotech's prostate cancer project TASQ
2006-09-18
Active Biotech to Present at the UBS Global Life Sciences Conference
2006-09-07
Active Biotech publishes pre-clinical data regarding the TASQ prostate cancer project
2006-09-05
Laquinimod Phase IIb Trial confirms efficacy and favorable safety profile and shows significant reduction in the rate of inflammatory disease activity
2006-08-10
Active Biotech Interim Report January-June 2006
2006-08-08
Invitation Conference Call - Active Biotech AB
2006-06-26
Active Biotech's project 57-57 presented at EULAR in Amsterdam
2006-06-05
Active Biotech's ANYARA cancer project presented at ASCO in Atlanta
2006-05-12
Active Biotech to Present at the Rodman & Renshaw
2006-05-11
Active Biotech Interim Report January-March 2006
2006-05-09
ACTIVE BIOTECH AND CHELSEA THERAPEUTICS TO CO-DEVELOP PORTFOLIO
2006-05-08
Invitation Conference Call - Active Biotech AB
2006-04-27
Annual General Meeting of Active Biotech AB
2006-04-04
Active Biotech at BIO 2006
2006-03-28
Invitation to Annual General Meeting of Shareholders
2006-03-27
Patent application submitted regarding the mode of action for quinoline compounds
2006-03-09
RhuDex® successfully concludes Phase I clinical trials
2006-03-06
Active Biotech to Present at the Cowen & Company 26th Annual Health Care Conference
2006-02-16
Active Biotech Year-end Report January-December 2005
2006-02-13
Invitation Teleconference - Active Biotech AB
2006-01-16
Active Biotech's nominations committee appointed
2005-12-19
Active Biotech Advances 57-57 Project
2005-12-15
Active Biotech Reports Interim Results of ANYARA Phase I Clinical Trial
2005-11-08
Active Biotech Commences Clinical Phase I Combination Study of ANYARA and Taxotere®
2005-11-03
Active Biotech to Present at the SG Cowen & Company 6th Annual
2005-11-02
Active Biotech Interim Report January - September 2005
2005-11-01
Active Biotech to Present at The Rodman & Renshaw Techvest
2005-10-28
Invitation Teleconference - Active Biotech AB
2005-09-30
Active Biotech presents survival data on cancer drug
2005-09-30
Confirmed ANYARA tumor PET localization in cancer patients
2005-09-29
Active Biotech presents survival data on cancer drug
2005-09-29
Confirmed ANYARA tumor PET localization in cancer patients
2005-09-27
Confirmed favorable safety profile for Active Biotech's oral MS drug
2005-09-22
Active Biotech to present at UBS Global Life Sciences Conference
2005-08-11
Active Biotech Interim report January - June 2005
2005-08-09
Invitation Teleconference - Active Biotech AB
2005-07-18
Phase I study for Active Biotech's SLE project 57-57 successfully concluded
2005-07-07
Active Biotech's new share issue oversubscribed
2005-06-28
TEVA AND ACTIVE BIOTECH ANNOUNCE THE SUBMISSION OF AN IND TO THE FDA FOR LAQUINIMOD, AN ORAL PRODUCT FOR THE TREATMENT OF RELAPSING MS
2005-06-15
Meet Active Biotech at BIO2005 Annual Convention, June 19-22 in Philadelphia, USA
2005-05-18
Active Biotech's preferential rights issue for approximately 169 MSEK
2005-05-12
Active Biotech Interim Report January-March 2005
2005-05-09
Invitation Teleconference - Active Biotech AB
2005-05-09
RhuDex® for the treatment of RA enters Phase I clinical trials
2005-04-29
Active Biotech to present at Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference
2005-04-22
Annual General Meeting of Active Biotech AB
2005-03-24
Invitation to Annual General Meeting of Shareholders
2005-03-22
Teva and Active Biotech Announce That Laquinimod Phase II Data Has Been Published Today in Neurology
2005-03-10
Active Biotech to present at SG Cowen & Co. 25th Annual Health Care Conference
2005-02-17
Year-end report Jan-Dec 2004
2005-02-14
Invitation Teleconference - Active Biotech AB
2005-02-03
Shareholder-friendly measures to promote liquidity
2004-12-20
Active Biotech's nominations committee appointed
2004-12-15
Convertible debentures issue fully subscribed
2004-12-13
Active Biotech commences clinical studies in prostate cancer patients
2004-12-02
Approved patent in the U.S. for Active Biotech's cancer project TTS
2004-12-01
FDA has granted Fast Track Status to Active Biotech's TTS cancer project
2004-11-15
Active Biotech to present at SG Cowen & Co 5th Annual Global Health Care Conference
2004-11-09
Extraordinary General Meeting - Active Biotech AB
2004-11-05
Active Biotech Interim Report January-September 2004
2004-11-03
Invitation Teleconference - Active Biotech AB
2004-11-02
Active Biotech commences clinical studies for 57-57 project against SLE
2004-10-25
Active Biotech to present at Rodman & Renshaw Techvest 6th Annual Healthcare Conference
2004-10-22
Announcement of debenture issue
2004-10-22
Invitation to Extraordinary General Meeting of Shareholders
2004-10-18
Active Biotech's Capital Market Meeting with Teva Pharmaceutical Industries in Stockholm on October 19
2004-09-22
Active Biotech to present at UBS Global Life Sciences Conference
2004-09-15
Invitation to Active Biotech's capital market meeting with Teva Pharmaceutical Industries in Stockholm on October 19
2004-09-15
Active Biotech proposes a rights issue of convertible debentures totalling SEK 150 M
2004-08-25
Correction of information in the magazine Affärsvärlden
2004-08-24
FEDERAL TRADE COMMISSION CLEARS TEVA/ACTIVE BIOTECH AGREEMENT
2004-08-12
Active Biotech - Interim report Jan-Jun 2004
2004-08-09
Invitation Teleconference - Active Biotech AB
2004-06-14
TEVA AND ACTIVE BIOTECH ANNOUNCE AGREEMENT FOR LAQUINIMOD
2004-06-03
Active Biotech AB and Strathmann Biotec AG conclude agreement regarding manufacturing of TTS cancer product
2004-06-02
Meet Active Biotech at BIO2004 Annual Convention, June 6-9 in San Francisco, CA
2004-05-13
Avidex and Active Biotech enter collaboration to develop fusion proteins combining monoclonal mTCRs with superantigens
2004-05-13
Active Biotech Interim Report January-March 2004
2004-05-11
Invitation Teleconference - Active Biotech AB
2004-04-27
Active Biotech at the 56th Annual Meeting of the American Academy of Neurology
2004-04-22
Annual General Meeting of Active Biotech AB
2004-04-02
Active Biotech - Annual Report 2003
2004-04-01
Active Biotech and PowderJect Pharmaceuticals have reached an amicable settlement of their arbitration
2004-03-25
Pancreatic cancer suitable for treatment with Active Biotech's TTS cancer products
2004-03-24
Invitation to Annual General Meeting of Shareholders
2004-02-27
Active Biotech focuses operations on development projects
2004-02-12
Active Biotech - Year End Report, January-December 2003
2004-02-09
Invitation Teleconference - Active Biotech AB
2004-01-02
Active Biotech AB on Attract 40
2003-12-18
Active Biotech - the first day for trading in the new single class of shares will be December 19
2003-12-17
Positive results confirmed in final report for Active Biotech's TTS cancer product
2003-12-08
Decision by Extraordinary General Meeting of Active Biotech AB (publ)
2003-11-10
Invitation to Extraordinary General Meeting of Shareholders
2003-11-06
Active Biotech Interim Report January - September 2003
2003-10-27
Positive preclinical results for Active Biotech's project 57-57 for the treatment of SLE
2003-09-17
Active Biotech to present at UBS Global Life Sciences Conference
2003-09-16
Invitation Teleconference - Active Biotech AB
2003-09-16
Primary endpoint reached in Phase II clinical trial of Active Biotech's substance for oral treatment of multiple sclerosis
2003-08-14
Active Biotech Interim Report January-June 2003
2003-08-11
Invitation Teleconference - Active Biotech AB
2003-07-28
CPMP recommends registration for Dukoral in the EU
2003-06-18
Meet Active Biotech at BIO2003 Annual Convention, June 22-25 in Washington D.C
2003-06-12
Active Biotech rejects the claim made by PowderJect Pharmaceuticals
2003-06-04
First day for trading in Active Biotech's newly issued B shares will be on Friday June 6, 2003
2003-06-02
Interim evaluation of Active Biotech's TTS CD2 for renal cancer shows encouraging results in clinical Phase IIa
2003-05-23
Final count confirms Active Biotech's new share issue oversubscribed
2003-05-19
Active Biotech's new share issue oversubscribed
2003-05-15
Active Biotech Interim Report January-March 2003
2003-05-12
Invitation Teleconference - Active Biotech AB
2003-05-08
Cancer-treatment substance TTS CD3 enters Phase I clinical trials in US
2003-04-23
Indications regarding prolonged survival with Active Biotech's TTS cancer drug
2003-04-11
Annual General Meeting of Active Biotech AB
2003-03-13
Invitation to Annual General Meeting of Shareholders
2003-02-13
Active Biotech - SEK 225 million (approx. 25 million) rights issue
2003-02-13
Active Biotech Quarterly Report Oct-Dec, Full Year 2002
2003-02-10
Invitation Teleconference - Active Biotech AB
2003-01-29
Positive results from preliminary clinical studies of Active Biotech's prostate cancer drug
2003-01-15
Håkan Åström leaves the Board of Active Biotech
2003-01-09
Application approved by the FDA for start of TTS clinical programme
2002-11-14
Active Biotech Interim Report July-September 2002
2002-11-13
New date for Active Biotech’s Q3 Teleconference
2002-11-04
Invitation Teleconference - Active Biotech AB
2002-10-10
New results from Active Biotech’s SAIK-MS project
2002-08-15
Active Biotech Interim Report April-June 2002
2002-08-12
Teleconference - Active Biotech AB
2002-06-24
Active Biotech has selected a new Candidate Drug for the treatment of SLE
2002-05-31
Active Biotech’s drug for the treatment of Multiple Sclerosis
2002-05-16
Active Biotech AB, Interim Report January-March 2002
2002-04-19
Annual General Meeting of Shareholders in Active Biotech 18 April 2002
2002-04-11
Active Biotech's Phase II study of SAIK-MS has started
2002-04-04
Active Biotech and Avidex sign Licensing Agreement
2002-02-06
Active Biotech's application to start Phase II pancreas cancer trial approved by UK authorities
2002-02-04
Active Biotech obtains US patent for cancer product
2001-11-26
Active Biotech signs licensing agreement with Oxigene regarding benzamide IP
2001-11-13
Active Biotech's application for TTS Phase II trial approved by UK authorities
2001-10-25
Phase II clinical trial for Active Biotech's multiple sclerosis drug SAIK-MS
2001-08-06
Active Biotech signs Letter of Intent with Avidex Ltd.
2001-07-03
Active Biotech sells SBL Vaccin to PowderJect Pharmaceuticals
2001-06-26
Positive results reported by Active Biotech's TTS Phase I cancer study
2001-05-14
The Active Biotech Group Interim Report January - March 2001
2000-10-25
Active Biotech receives major new order for SBL Cholera Vaccine worth MSEK 11.5
2000-10-19
ACTIVE BIOTECH - EXTRA SHAREHOLDERS´ MEETING 19 OCTOBER 2000
2000-08-18
The Active Biotech Group Half-Year Accounts January - June 2000
2000-08-08
Active Biotech and SmithKline Beecham agree to close collaboration regarding vaccines against travellers diarrhoea
2000-08-08
Active Biotech concludes agreement with Aventis Pasteur
2000-08-02
Active Biotech AB accepts offer from Carl Bennet AB on shares in Lifco AB
2000-05-26
Active Biotech Quarterly Report January - March 2000
2000-04-14
ACTIVE BIOTECH SHAREHOLDERS' MEETING 12 APRIL 2000
2000-03-29
Preliminary results from the first Phase lll-study of the ETEC-vaccine
2000-03-15
Invitation to Annual Meeting of Shareholders
2000-03-02
Patent for SAIK-MS approved in the USA
2000-02-21
Active Biotech Group Annual Accounts Report January - December 1999
2000-02-11
The Swedish Medical Products Agency has approved for Active Biotech to expand Phase I-trials and include patients with multiple sclerosis
2000-01-10
New production manager for Active Biotech
1999-12-22
PRESS RELEASE
1999-11-24
Active Biotech Group Interim Report 1 January - 30 September 1999 <br>
1999-11-12
Altered day regarding financial information for Active Biotech
1999-09-24
Increased institutional ownership in Active Biotech
1999-08-27
Half Year Report January - June 1999
1999-08-03
Active Biotech gets international order for cholera vaccine after recommendation from WHO
1999-06-29
Active Biotech's drug against MS in Phase I trials 6 months ahead of plan
1999-06-16
Active Biotech and OXiGENE enter into research collaboration within the field of inflammatory diseases
1999-06-08
Active Biotech gains strength with a new Head of Preclinical Research
1999-05-20
The Active Biotech Group Quarterly Report January - March 1999
1999-05-12
Topics from the Managing Director's Speech at the Annual General Meeting of Active Biotech
1999-04-23
Invitation to Annual Meeting of Shareholders
1999-03-29
Active Biotech concentrates upon cancer diagnostics
1999-03-01
Active Biotech Group Annual Accounts Report January - December 1998
1999-01-15
NOVEL PRODUCT IDENTIFIED FOR TOOTH DECAY
1998-12-29
Active Biotech acquires 100 % in Transport AB Movera
1998-12-22
Active Biotech sells its real estate in Lund for SEK 320 M with a capital gain of SEK 80M
1998-12-16
Sven Andréasson new President & CEO of Active Biotech
1998-11-19
Active Biotech Group Interim Report 1 January - 30 September 1998
1998-11-17
BioPhausia and Active Biotech to co-operate in cancer project
1998-09-07
SUBSTANTIAL ACQUISITION OF SHARES
1998-07-02
Very high level of participation in Active Biotech's warrants programme for personnel
1998-06-29
Active Biotech steps up efforts in ETEC and cholera vaccine through acquisition of VITEC
1998-06-05
Active Biotech AB's directed new share issue fully subscribed
1998-05-20
New issue fully subscribed
1998-04-17
Active Biotech's Annual General Meeting approved the acquisition of the Lund Research Center
1998-03-10
New Head of Research at Active Biotech
1998-03-09
Active Biotech - new force in biotechnology
1997-12-19
Active Biotech acquires Lund Research Center from Pharmacia & Upjohn
1997-10-20
ACTIVE becomes Active Biotech - operations concentrated on biotechnology
1997-10-05
ACTIVE to concentrate on biotechnology
1997-05-29
Agreement with Swedish Government on acquisition of SBL Vaccin AB
1997-05-13
SBL Vaccin acquisition approved by ACTIVE's Annual General Meeting
1997-05-12
ACTIVE acquires SBL Vaccin AB from the Swedish State
In Swedish
2013-05-16
Nya data som presenteras på ASCO visar på Active Biotechs stora engagemang i cancerforskning
2013-05-16
Årsstämma i Active Biotech AB
2013-04-25
Active Biotech AB Delårsrapport januari - mars 2013
2013-04-25
Active Biotech och Ipsen uppdaterar analysplanen för studien 10TASQ10 vilken utvärderar tasquinimod för behandling av prostatacancer
2013-04-15
Årsredovisning 2012 Active Biotech AB (publ)
2013-04-11
Active Biotech - Kallelse till årsstämma
2013-03-28
Antal aktier och röster i Active Biotech
2013-03-21
TIDIG BEHANDLINGSSTART MED LAQUINIMOD VISAR SIGNIFIKANT MINDRE RISK FÖR FUNKTIONSNEDSÄTTNING - TREÅRSRESULTAT FRÅN ALLEGRO, EN KLINISK STUDIE I RELAPSERANDE REMITTERANDE MULTIPEL SKLEROS- PATIENTER
2013-03-06
FÖRSTA PATIENTEN REKRYTERAD TILL DEN TREDJE FAS III-STUDIEN AV ORAL LAQUINIMOD FÖR BEHANDLING AV RELAPSERANDE REMITTERANDE MULTIPEL SKLEROS
2013-03-06
Active Biotech tillförs 270 miljoner kronor genom en riktad nyemission till Investor
2013-02-14
Active Biotech AB Bokslutsrapport januari - december 2012
2013-01-28
Resultat från Active Biotechs fas II/III-studie med ANYARA för behandling av njurcancer
2013-01-03
Active Biotech presenterar på JP Morgan 31st Annual Healthcare Conference
2012-12-12
Laquinimod highlights från Tevas investerardag den 11 december
2012-12-11
Teva håller investerarmöte den 11 december
2012-12-10
Active Biotechs och Ipsens kliniska fas III-studie med tasquinimod i prostatacancer fullrekryterad
2012-11-15
Active Biotechs valberedning utsedd
2012-11-09
Active Biotech AB Delårsrapport januari - september 2012
2012-10-22
POSITIVA FAS IIa-DATA FÖR LAQUINIMOD FÖR BEHANDLING AV AKTIV CROHNS SJUKDOM
2012-10-19
Active Biotechs samarbetspartner Ipsen inleder en "proof of concept"-studie med tasquinimod i ytterligare cancerindikationer
2012-10-03
Ipsen inleder en underhållsterapi fas II-studie med tasquinimod i kastratresistent metastaserad prostatacancer
2012-10-01
Tasquinimod biomarkörsdata från fas II presenterade på ESMO 2012
2012-09-06
Active Biotech presenterar på Rodman & Renshaw Annual Global Investment Conference
2012-08-10
Active Biotech AB Delårsrapport januari - juni 2012
2012-08-08
TEVA PÅBÖRJAR EN TREDJE FAS III-STUDIE MED LAQUINIMOD I TABLETTFORM FÖR BEHANDLING AV RELAPSERANDE REMITTERANDE MULTIPEL SKLEROS
2012-07-17
ACTIVE BIOTECH MEDDELAR ATT DET EUROPEISKA LÄKEMEDELSVERKET ACCEPTERAT REGISTRERINGSANSÖKAN AV LAQUINIMOD FÖR BEHANDLING AV RELAPSERANDE REMITTERANDE MS OCH UTVÄRDERINGSPROCESSEN PÅBÖRJAS
2012-06-04
Active Biotechs and Ipsens läkemedelskandidat tasquinimod uppvisar förlängd överlevnadstid för kastratresistenta prostatacancerpatienter
2012-05-31
Active Biotech presenterar på Jefferies 2012 Global Healthcare Conference
2012-05-29
Active Biotech inbjuder till Kapitalmarknadsdag
2012-05-21
600 patienter rekryterade i Active Biotechs och Ipsens kliniska fas III-studie med tasquinimod
2012-05-18
Active Biotech och Ipsen presenterar överlevnadsdata från fas II-studien av tasquinimod på 2012 ASCO Annual Meeting
2012-05-11
Årsstämma i Active Biotech AB
2012-04-26
Active Biotech AB Delårsrapport januari - mars 2012
2012-04-17
Årsredovisning 2011 Active Biotech AB (publ)
2012-04-11
Active Biotech: Kallelse till årsstämma
2012-03-15
Fas III-studien med Tevas orala laquinimod publicerad i The New England Journal of Medicine påvisar den kliniska nyttan för patienter med multipel skleros
2012-02-24
Active Biotech och Ipsen presenterar på konferensen 27th European Association of Urology (EAU) för första gången långtidssäkerhetsdata från fas II-studien av tasquinimod (TASQ)
2012-02-16
Active Biotech AB Bokslutsrapport januari - december 2011
2012-01-23
Active Biotechs prostatacancerprojekt TASQ i fas I klinisk studie som kombinationsterapi
2012-01-04
Active Biotech presenterar på JP Morgan 30th Annual Healthcare Conference
2011-11-10
Active Biotechs valberedning utsedd
2011-11-03
Active Biotech AB Delårsrapport januari - september 2011
2011-11-02
Information angående Active Biotechs läkemedelskandidat laquinimod
2011-10-19
LÄKEMEDELSKANDIDATEN LAQUINIMOD - EN LOVANDE UNIK ORAL BEHANDLING MOT RRMS
2011-09-20
Active Biotechs prostatacancerprojekt TASQ presenterat i Journal of Clinical Oncology
2011-08-11
Active Biotech AB Delårsrapport januari - juni 2011
2011-08-01
RESULTAT FRÅN FAS III-STUDIEN BRAVO STÄRKER LAQUINIMODS UNIKA PROFIL FÖR BEHANDLING AV MULTIPEL SKLEROS
2011-06-30
Antal aktier och röster i Active Biotech
2011-06-08
Active Biotech presenterar på Jefferies 2011 Global Healthcare Conference
2011-05-31
Antal aktier och röster i Active Biotech
2011-05-26
Active Biotech presenterar data rörande projektet 57-57 på EULAR
2011-05-06
Årsstämma i Active Biotech AB
2011-04-29
Antal aktier och röster i Active Biotech
2011-04-28
Active Biotech AB Delårsrapport januari - mars 2011
2011-04-26
Active Biotechs samarbetspartner Teva kommenterar resultaten från studien DEFINE i multipel skleros
2011-04-18
Active Biotech och Ipsen tecknar brett samarbetsavtal för utveckling och kommersialisering av TASQ inom uro-onkologi
2011-04-14
Valberedningen i Active Biotech föreslår ytterligare en ny styrelseledamot
2011-04-12
LAQUINIMOD FÖR ORAL BEHANDLING AV MULTIPEL SKLEROS GAV BÅDE SIGNIFIKANT MINSKAD SJUKDOMSAKTIVITET OCH FUNKTIONSNEDSÄTTNING MED BIBEHÅLLEN GOD SÄKERHET OCH TOLERABILITET
2011-04-11
Teva håller webbkonferens avseende resultaten från fas III-studien ALLEGRO av oral laquinimod för behandling av multipel skleros
2011-04-06
Årsredovisning 2010 Active Biotech AB (publ)
2011-04-05
Kallelse till årsstämma
2011-03-15
Helén Tuvesson utsedd till forskningschef på Active Biotech
2011-02-28
Antal aktier och röster i Active Biotech
2011-02-18
Active Biotechs prostatacancerprojekt TASQ presenterat på 2011 Genitourinary Cancers Symposium
2011-02-10
Active Biotech AB Bokslutsrapport januari - december 2010
2011-01-27
Active Biotech genomför riktad nyemission om 375 miljoner kronor
2011-01-26
Active Biotech offentliggör placering av nya aktier
2010-12-30
Antal aktier och röster i Active Biotech
2010-12-09
TEVA OCH ACTIVE BIOTECH OFFENTLIGGÖR FRAMGÅNGSRIKA FAS III-RESULTAT FÖR LAQUINIMOD FÖR ORAL BEHANDLING AV MULTIPEL SKLEROS
2010-11-18
Active Biotechs projekt 57-57 rekommenderat som särläkemedel
2010-11-03
Active Biotechs valberedning utsedd
2010-10-29
Antal aktier och röster i Active Biotech
2010-10-27
Active Biotech AB Delårsrapport januari - september 2010
2010-10-15
NYA DATA SOM UTVÄRDERAR LAQUINIMIOD FÖR BEHANDLING AV MULTIPEL SKLEROS UPPVISAR NERVSKYDDANDE EFFEKTER
2010-09-30
Antal aktier och röster i Active Biotech
2010-09-20
LAQUINIMOD I TABLETTFORM UPPVISAR BIBEHÅLLEN EFFEKT OCH SÄKERHET I PATIENTER MED MULTIPEL SKLEROS
2010-09-16
Active Biotech presenterar på UBS Global Life Sciences Conference
2010-09-09
Active Biotech presenterar på Rodman & Renshaw 12th Annual Healthcare Conference
2010-08-11
Active Biotech AB Delårsrapport januari - juni 2010
2010-07-30
Antal aktier och röster i Active Biotech
2010-06-30
Antal aktier och röster i Active Biotech
2010-06-10
Active Biotechs kapitalmarknadsdag
2010-06-07
Active Biotechs prostatacancerprojekt TASQ presenterat på ASCO
2010-05-21
Active Biotechs prostatacancerprojekt presenteras på ASCO
2010-05-18
Active Biotechs njurcancerprojekt ANYARA presenteras i Journal of Immunotherapy
2010-05-18
Active Biotech inbjuder till Kapitalmarknadsdag
2010-05-17
Active Biotechs prostatacancerprojekt TASQ presenteras i Molecular Cancer
2010-05-17
Active Biotech to Present at the Rodman & Renshaw 6th Annual Global Healthcare Conference
2010-05-07
Årsstämma i Active Biotech AB
2010-04-30
Antal aktier och röster i Active Biotech
2010-04-22
Active Biotech AB Delårsrapport januari - mars 2010
2010-04-20
Årsredovisning 2009 Active Biotech AB (publ)
2010-04-15
NYA DATA VISAR ATT LAQUINIMODS IMMUNMODULERANDE EFFEKT PÅ MULTIPEL SKLEROS ÄVEN KAN VARA NERVSKYDDANDE
2010-04-06
Kallelse till årsstämma
2010-04-01
Active Biotech tillförs 149 miljoner kronor genom en riktad nyemission
2010-03-31
Antal aktier och röster i Active Biotech
2010-02-26
Antal aktier och röster i Active Biotech
2010-02-11
Active Biotech AB Bokslutsrapport, januari - december 2009
2010-02-10
Explorativa data presenterade för Active Biotechs projekt ANYARA
2010-02-08
TEVA FÖRVÄRVAR MARKNADSRÄTTIGHETERNA FÖR LAQUINIMOD I NORDEN OCH BALTIKUM
2009-12-14
Primärt mål uppnått i klinisk fas II-prövning för Active Biotechs prostatacancerprojekt TASQ
2009-11-05
Active Biotechs valberedning utsedd
2009-11-05
Active Biotech AB Delårsrapport, januari - september 2009
2009-10-05
Det brittiska läkemedelsverket ger klartecken för fortsatt klinisk utveckling av RhuDex
2009-09-25
Active Biotechs prostatacancerprojekt TASQ presenteras i British Journal of Cancer
2009-09-17
Active Biotech presenterar på UBS Global Life Sciences Conference
2009-09-11
LAQUINIMODS IMMUNMODULERANDE MEKANISM HAR BÅDE NERVSKYDDANDE OCH ANTI-INFLAMMATORISKA EGENSKAPER
2009-09-08
Laquinimod presenteras på ECTRIMS
2009-09-04
Active Biotech presenterar på Rodman & Renshaw 11th Annual Healthcare Conference
2009-08-07
Ny information kring RhuDex(TM)
2009-08-06
Active Biotech AB Delårsrapport januari-juni 2009
2009-07-28
Active Biotechs cancerprojekt ANYARA presenteras i Journal of Clinical Oncology
2009-06-30
Antal aktier och röster i Active Biotech
2009-06-25
BRAVO-studien för laquinimod fullrekryterad
2009-06-15
Active Biotechs nyemission kraftigt övertecknad
2009-06-11
Active Biotech presenterar data rörande SLE-projektet 57-57 på EULAR
2009-06-08
Patientrekryteringen till Active Biotechs kliniska fas II-studie för TASQ avslutad
2009-06-01
Patientrekryteringen till Active Biotechs kliniska fas III-studie för ANYARA avslutad
2009-05-18
Offentliggörande av prospekt avseende nyemission i Active Biotech AB (publ)
2009-05-08
Årsstämma i Active Biotech AB
2009-04-28
NYA RÖN KRING VERKNINGSMEKANISMEN FÖR LAQUINIMOD, EN NY ORAL BEHANDLING AV MULTIPEL SKLEROS
2009-04-28
Active Biotech presenterar S100A9 som en målmolekyl för quinolinsubstanser
2009-04-23
Active Biotech AB Delårsrapport januari-mars 2009
2009-04-06
Årsredovisning 2008 Active Biotech AB (publ)
2009-04-06
Styrelsen för Active Biotech AB föreslår årsstämman att besluta om en garanterad företrädesemission om cirka 256 MSEK
2009-04-06
Kallelse till årsstämma
2009-02-12
LAQUINIMOD FÖR ORAL BEHANDLING AV MULTIPEL SKLEROS ERHÅLLER FAST TRACK-STATUS FRÅN FDA
2009-02-12
Active Biotech AB Bokslutsrapport januari-december 2008
2009-01-26
Information från Active Biotech AB:s valberedning
2008-12-10
Active Biotechs cancerprojekt ANYARA: Kombination med etablerade tumörläkemedel lovande
2008-11-28
Active Biotechs valberedning utsedd
2008-11-18
Patientrekryteringen till den kliniska fas III-studien för laquinimod avslutad
2008-11-14
Active Biotech AB Delårsrapport januari-september 2008
2008-10-28
Active Biotech presenterar nya data rörande SLE-projektet 57-57 på American College of Rheumatology
2008-10-17
Ny information kring RhuDex®
2008-09-18
LAQUINIMOD UPPVISAR SIGNIFIKANT OCH BIBEHÅLLEN VERKAN PÅ SJUKDOMEN MULTIPEL SKLEROS
2008-09-17
Active Biotech presenterar på UBS 2008 Global Life Sciences Conference
2008-08-06
Active Biotech AB Delårsrapport januari-juni 2008
2008-07-23
Tomas Leanderson ny verkställande direktör i Active Biotech
2008-07-16
TEVA REKRYTERAR PATIENTER TILL EN ANDRA STOR GLOBAL REGISTRERINGSGRUNDANDE FAS III-STUDIE AV ORAL LAQUINIMOD FÖR BEHANDLING AV RELAPSERANDE REMITTERANDE MULTIPEL SKLEROS
2008-06-30
Antal aktier och röster i Active Biotech
2008-06-24
Positiva resultat för RhuDex® i klinisk fas IIa-studie
2008-06-20
Active Biotechs orala MS-läkemedel laquinimod presenteras i den vetenskapliga tidskriften The Lancet
2008-06-12
Active Biotechs nyemission fulltecknad
2008-05-15
Offentliggörande av prospekt avseende nyemission i Active Biotech AB (publ)
2008-05-13
Active Biotechs ANYARA går vidare till fas III kliniska prövningar
2008-05-08
Årsstämma i Active Biotech AB
2008-04-24
Active Biotech AB Delårsrapport januari-mars 2008
2008-04-23
Årsredovisning 2007 Active Biotech AB (publ)
2008-04-15
Prekliniska data presenterade för Active Biotechs ANYARA-teknologi
2008-04-09
Kallelse till årsstämma
2008-04-07
Styrelsen för Active Biotech AB föreslår årsstämman att besluta om en garanterad företrädesemission om cirka 160 MSEK
2008-02-14
Active Biotech Bokslutsrapport januari-december 2007
2007-11-22
Active Biotechs valberedning utsedd
2007-11-08
Active Biotech Delårsrapport jan-sep 2007
2007-11-07
Inbjudan Telekonferens - Active Biotech AB
2007-11-07
PATIENTREKRYTERING TILL REGISTRERINGSGRUNDANDE KLINISK FAS III-STUDIE INLEDD FÖR ORALT LAQUINIMOD FÖR BEHANDLING AV RELAPSERANDE REMITTERANDE MULTIPEL SKLEROS
2007-11-01
Active Biotech to Present at the Rodman & Renshaw 9th Annual Healthcare Conference
2007-10-24
Active Biotechs cancerprojekt ANYARA säkert i kombination med Taxotere®
2007-10-02
RhuDex®; MediGene erhåller patent i USA
2007-08-10
FDA godkänner IND för start av TASQ fas II-studier
2007-08-09
Active Biotech Delårsrapport januari-juni 2007
2007-07-26
Active Biotechs cancerläkemedel ANYARA erhåller orphan drug-status av EMEA
2007-06-18
Active Biotech presenterar nya prekliniska data för 57-57 på "8th World Congress on Inflammation"
2007-06-15
Nya positiva prekliniska data för Active Biotechs RA-projekt I-3D
2007-06-07
ACTIVE BIOTECH OCH TEVA INLEDER REGISTRERINGSGRUNDANDE FAS III-PRÖVNINGAR AV SITT ORALA MS-PREPARAT LAQUINIMOD
2007-05-04
Active Biotech Delårsrapport januari-mars 2007
2007-05-01
Laquinimod, en ny substans i tablettform, uppvisar en signifikant minskning av sjukdomsaktiviteten i patienter med relapserande remitterande multipel skleros (RRMS)
2007-04-20
Årsstämma i Active Biotech AB
2007-03-28
Förtida lösen av Active Biotechs konvertibellån
2007-03-27
Active Biotech publicerar data gällande prostatacancerprojektet TASQ
2007-03-22
Kallelse till årsstämma
2007-03-15
Valberedningens förslag till beslut på Active Biotechs årsstämma
2007-03-13
Active Biotechs I-3D klinisk mikrodos-studie avslutad
2007-03-09
Positiva kliniska data för TASQ - Active Biotechs projekt för behandling av prostatacancer
2007-02-15
Active Biotech påkallar förtida återbetalning av konvertibellån
2007-02-15
Active Biotech Bokslutsrapport 2006
2007-02-14
Active Biotechs nyemission övertecknad
2007-01-23
RhuDex® inleder kliniska fas II-prövningar för behandling av ledgångsreumatism
2007-01-12
Active Biotechs nomineringskommitté utsedd
2007-01-04
Active Biotechs garanterade företrädesemission om 240 MSEK; Korrigering
2006-12-18
Active Biotech genomför garanterad företrädesemission om cirka 240 MSEK
2006-12-13
Active Biotechs nya cancerbehandling ANYARA uppvisar farmakologisk effekt i patienter i framgångsrika fas I-studier
2006-11-21
Active Biotech erhåller 5 miljoner kronor från VINNOVA
2006-11-02
Active Biotech Delårsrapport Jan-Sept 2006
2006-10-09
Maria Borelius lämnar styrelsen i Active Biotech AB
2006-09-20
Positiva kliniska resultat för Active Biotechs prostatacancerprojekt TASQ
2006-09-07
Active Biotech publicerar prekliniska data gällande prostatacancerprojektet TASQ
2006-09-05
Fas IIb-studie bekräftar laquinimods effektivitet och fördelaktiga säkerhetsprofil samt uppvisar en signifikant minskning av inflammatorisk sjukdomsaktivitet
2006-08-10
Active Biotech Delårsrapport Januari-Juni 2006
2006-08-08
Inbjudan Telekonferens - Active Biotech AB
2006-06-26
Active Biotechs projekt 57-57 presenterat på EULAR i Amsterdam
2006-06-05
Active Biotechs cancerprojekt ANYARA presenterat på ASCO i Atlanta
2006-05-11
Active Biotech Delårsrapport januari-mars 2006
2006-05-09
ACTIVE BIOTECH OCH CHELSEA THERAPEUTICS TECKNAR SAMARBETSAVTAL
2006-05-08
Inbjudan Telekonferens - Active Biotech AB
2006-04-27
Bolagsstämma i Active Biotech AB
2006-03-28
Kallelse till årsstämma
2006-03-27
Patentansökan inskickad rörande quinolinsubstansernas verkningsmekanism
2006-03-09
RhuDex® avslutar fas I-studier positivt
2006-02-16
Active Biotech Bokslutsrapport januari-december 2005
2006-02-13
Inbjudan Telekonferens - Active Biotech AB
2006-01-16
Active Biotechs nomineringskommitté utsedd
2005-12-19
Active Biotech har startat klinisk prövning med patienter för projektet 57-57
2005-12-15
Active Biotech rapporterar interimsresultat från ANYARA fas I klinisk studie
2005-11-08
Active Biotech inleder klinisk fas I kombinationsstudie med ANYARA och Taxotere®
2005-11-02
Active Biotech Delårsrapport Januari-September 2005
2005-10-28
Inbjudan Telekonferens - Active Biotech AB
2005-09-30
Active Biotech presenterar överlevnadsdata för cancerläkemedel
2005-09-30
Bekräftad tumörlokalisation av ANYARA hos cancerpatienter med hjälp av PET
2005-09-29
Active Biotech presenterar överlevnadsdata för cancerläkemedel
2005-09-29
Bekräftad tumörlokalisation av ANYARA hos cancerpatienter med hjälp av PET
2005-09-27
Fördelaktig säkerhetsprofil bekräftad för Active Biotechs orala MS-läkemedel
2005-08-11
Active Biotech AB Delårsrapport Januari-juni 2005
2005-08-09
Inbjudan Telekonferens - Active Biotech AB
2005-07-18
Fas I-studie positivt avslutad för Active Biotechs SLE-projekt 57-57
2005-07-07
Active Biotechs nyemission övertecknad
2005-06-28
TEVA OCH ACTIVE BIOTECH LÄMNAR IN IND-ANSÖKAN TILL FDA FÖR LAQUINIMOD; EN ORAL PRODUKT FÖR BEHANDLING AV RELAPSERANDE MS
2005-05-18
Active Biotechs företrädesemission om cirka 169 MSEK
2005-05-12
Active Biotech Delårsrapport januari-mars 2005
2005-05-09
Inbjudan Telekonferens - Active Biotech AB
2005-05-09
RhuDex för behandling av RA inleder fas I kliniska prövningar
2005-04-29
Active Biotech presenterar på Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference
2005-04-22
VDs anförande vid Active Biotechs bolagsstämma 2005
2005-04-22
Bolagsstämma i Active Biotech AB
2005-03-24
Kallelse till bolagsstämma
2005-03-22
Teva och Active Biotech meddelar att laquinimod fas II-data har publicerats idag i Neurology
2005-03-10
Active Biotech presenterar på SG Cowen & Co. 25th Annual Health Care Conference
2005-02-17
Bokslutsrapport jan-dec 2004
2005-02-14
Inbjudan Telekonferens - Active Biotech AB
2005-02-03
Likviditetsfrämjande och aktieägarvänliga åtgärder
2004-12-20
Active Biotechs nomineringskommitté utsedd
2004-12-15
Emissionen av konvertibla förlagsbevis i Active Biotech fulltecknad
2004-12-13
Active Biotech inleder kliniska studier i patienter med prostatacancer
2004-12-02
Godkänt patent i USA för Active Biotechs cancerprojekt TTS
2004-12-01
FDA har beviljat Fast Track-status för Active Biotechs cancerprojekt TTS
2004-11-15
Active Biotech presenterar på SG Cowen & Co 5th Annual Global Health Care Conference
2004-11-09
Extra bolagsstämma - Active Biotech AB
2004-11-05
Active Biotech Delårsrapport januari-september 2004
2004-11-03
Inbjudan Telekonferens - Active Biotech AB
2004-11-02
Active Biotech inleder kliniska studier för projekt 57-57 för SLE
2004-10-22
Kungörelse av emissionsbeslut
2004-10-22
Kallelse till extra bolagsstämma
2004-10-18
Active Biotechs kapitalmarknadsmöte med Teva Pharmaceutical Industries i Stockholm den 19 oktober
2004-09-15
Inbjudan till Active Biotechs kapitalmarknadsmöte med Teva Pharmaceutical Industries i Stockholm den 19 oktober
2004-09-15
Active Biotech föreslår nyemission av konvertibler om cirka 150 Mkr
2004-08-25
Rättelse av uppgifter i tidningen Affärsvärlden
2004-08-24
FEDERAL TRADE COMMISSION GODKÄNNER AVTAL MELLAN TEVA OCH ACTIVE BIOTECH
2004-08-12
Active Biotech - Delårsrapport januari-juni 2004
2004-08-09
Inbjudan Telekonferens - Active Biotech AB
2004-06-14
TEVA OCH ACTIVE BIOTECH SLUTER AVTAL KRING LAQUINIMOD FÖR ORAL BEHANDLING AV MULTIPEL SKLEROS
2004-06-03
Active Biotech AB och Strathmann Biotec AG tecknar avtal för produktion av cancerprodukten TTS
2004-05-13
Active Biotech tecknar samarbetsavtal med Avidex Ltd för utveckling av fusionsprotein med monoklonala TCR och superantigen
2004-05-13
Active Biotech Delårsrapport januari-mars 2004
2004-05-11
Inbjudan Telekonferens - Active Biotech AB
2004-04-27
Active Biotech vid 56th Annual Meeting of the American Academy of Neurology
2004-04-22
Bolagsstämma i Active Biotech AB
2004-04-02
Active Biotech - Årsredovisning 2003
2004-04-01
Active Biotech och Chiron har enats om en förlikning i skiljedomsförfarandet
2004-03-25
Active Biotechs cancerprodukt TTS verksam för behandling av pankreascancer
2004-03-24
Kallelse till bolagsstämma
2004-02-27
Active Biotech fokuserar verksamheten mot projekt i klinisk fas
2004-02-12
Active Biotech - Bokslutsrapport, januari-december 2003
2004-02-09
Inbjudan Telekonferens - Active Biotech AB
2004-01-15
Ingen relation till Biometron AB
2004-01-02
Active Biotech på Attract 40
2003-12-18
Active Biotech - handel med ett enda aktieslag inleds den 19 december
2003-12-17
Positiva resultat konfirmerade i slutrapport för Active Biotechs cancerprodukt TTS
2003-12-08
Beslut från extra bolagsstämma Active Biotech AB (publ)
2003-11-10
Kallelse till extra bolagsstämma
2003-11-06
Active Biotech Delårsrapport januari - september 2003
2003-10-27
Positiva prekliniska resultat för Active Biotechs projekt 57-57 för behandling av SLE
2003-09-16
Inbjudan Telekonferens - Active Biotech AB
2003-09-16
Active Biotechs orala substans för behandling av multipel skleros uppnår primärt mål i klinisk fas II-prövning
2003-08-14
Active Biotech Delårsrapport Januari-Juni 2003
2003-08-11
Inbjudan Telekonferens - Active Biotech AB
2003-07-25
CPMP rekommenderar registrering i EU för Dukoral
2003-06-12
Active Biotech avvisar krav från PowderJect Pharmaceuticals
2003-06-04
Första dag för handel i Active Biotechs nyemitterade B-aktier blir fredagen den 6 juni 2003
2003-06-02
Interimsutvärdering av Active Biotechs TTS CD2 mot njurcancer visar lovande resultat i klinisk Fas IIa
2003-05-23
Slutlig sammanräkning bekräftar överteckning i Active Biotechs nyemission
2003-05-19
Active Biotechs nyemission övertecknad
2003-05-15
Active Biotech Delårsrapport januari-mars 2003
2003-05-12
Inbjudan Telekonferens - Active Biotech AB
2003-05-08
Cancerpreparatet TTS CD3 i Fas I klinisk studie i USA
2003-04-23
Indikationer avseende förlängd överlevnad med Active Biotechs TTS- cancerpreparat
2003-04-11
Bolagsstämma i Active Biotech AB
2003-03-13
Kallelse till bolagsstämma
2003-02-13
Active Biotech - Företrädesemission om 225 Mkr
2003-02-13
Active Biotech Kvartalsrapport, Okt-Dec 2002, samt helår
2003-02-10
Inbjudan Telekonferens - Active Biotech AB
2003-01-29
Positiva resultat från inledande kliniska studier av Active Biotechs prostatacancer-preparat
2003-01-15
Håkan Åström lämnar styrelsen i Active Biotech
2003-01-09
Ansökan godkänd av FDA för start av kliniskt prövningsprogram för cancerprojektet TTS
2002-11-13
Active Biotech Kvartalsrapport Juli-September 2002
2002-11-13
Ny tid för Active Biotechs Q3 telefonkonferens
2002-11-08
Ändrat datum för Active Biotechs Q3-rapport
2002-11-04
Inbjudan Telekonferens - Active Biotech AB
2002-08-15
Active Biotech Kvartalsrapport April-juni 2002
2002-08-12
Telekonferens - Active Biotech AB
2002-06-24
Active Biotech har valt läkemedelskandidat för SLE-projektet
2002-05-31
Active Biotechs läkemedel mot multipel skleros
2002-05-16
Active Biotech AB, Kvartalsrapport januari-mars 2002
2002-05-15
Active Biotech Telefonkonferens, Q1
2002-04-19
Bolagsstämma i Active Biotech AB den 18 april 2002
2002-04-11
Active Biotechs Fas II-studie av SAIK-MS har inletts
2002-04-04
Active Biotech och Avidex tecknar licensavtal
2002-02-06
Active Biotechs ansökan godkänd av engelska myndigheter för start av Fas II pankreascancer studie
2002-02-04
Active Biotech får patent i USA för cancerprodukt
2001-11-26
Active Biotech tecknar licensavtal med Oxigene kring benzamidpatent
2001-11-13
Active Biotechs ansökan om klinisk prövning Fas II godkänd av brittiska myndigheter
2001-10-25
Fas II klinisk prövning för Active Biotechs läkemedel mot MS
2001-08-06
Active Biotech tecknar nytt samarbetsavtal
2001-07-03
Active Biotech säljer SBL Vaccin till PowderJect Pharmaceuticals
2001-06-26
Positiva resultat från Active Biotechs TTS Fas I cancerstudie
2001-05-09
Active Biotech-koncernen Kvartalsrapport januari-mars 2001
2001-02-15
Active Biotech-koncernen Bokslutskommuniké för verksamhetsåret 2000
2000-11-16
Active Biotech-koncernen: Delårsrapport januari - september 2000
2000-10-24
Active Biotech erhåller ny stor order på SBL Cholera Vaccine, värd 11,5 mkr
2000-10-19
EXTRA BOLAGSSTÄMMA - ACTIVE BIOTECH 19 OKTOBER 2000.
2000-08-17
Active Biotech-koncernen Halvårsbokslut januari - juni 2000
2000-08-08
Active Biotech och SmithKline Beecham avtalar om att avsluta samarbetet kring vaccin mot turistdiarré
2000-08-08
Active Biotech tecknar avtal med Aventis Pasteur
2000-08-02
Active Biotech AB accepterar Carl Bennet ABs bud på aktier i Lifco AB
2000-05-25
Active Biotech Kvartalsrapport januari - mars 2000
2000-04-13
Flaggningsmeddelande
2000-04-13
ACTIVE BIOTECHS BOLAGSTÄMMA 12 APRIL 2000
2000-04-13
MGA Holding ny storägare i Active Biotech AB
2000-04-13
Bo Håkanssons inledningsanförande vid Active Biotechs bolagsstämma 2000-04-12
2000-03-29
Preliminära resultat från Fas III-studier av ETEC-vaccinet
2000-03-15
Kallelse till bolagsstämma
2000-02-29
Patent för SAIK-MS beviljat i USA
2000-02-18
Bokslutskommuniké januari - december 1999
2000-02-11
Läkemedelsverket har godkänt att Active Biotech genomför en utvidgad Fas I-prövning som även inkluderar patienter med sjukdomen multipel skleros
1999-12-22
Ny produktionschef till Active Biotech
1999-12-21
PRESSRELEASE
1999-11-22
Active Biotech-koncernen Delårsrapport 1 januari - 30 september 1999
1999-11-12
Ändrad rapportdag för Active Biotech
1999-09-24
Ökat institutionellt ägande i Active Biotech
1999-08-26
Active Biotech-koncernen Halvårsbokslut januari - juni 1999
1999-08-02
Active Biotech får internationell order på koleravaccin efter rekommendation av WHO
1999-06-28
Active Biotechs läkemedel mot MS 6 månader tidigare i fas I
1999-06-16
Active Biotech och OXiGENE inleder forskningssamarbete inom området inflammation
1999-06-07
Active Biotech förstärker med ny preklinisk forskningschef
1999-05-31
Notering av aktierna i Wilh. Sonesson AB (publ) på O-listan vid Stockholms Fondbörs
1999-05-17
Active Biotech-koncernen Kvartalsrapport januari - mars 1999
1999-05-11
Många nyheter i VD-talet på Active Biotechs bolagsstämma
1999-04-29
Tidplan för utdelning av Wilh. Sonesson AB
1999-04-23
Kallelse till Bolagsstämma
1999-04-22
Årsredovisning 1998
1999-03-29
Active Biotech satsar på cancerdiagnostik
1999-02-25
Bokslutskommuniké januari - december 1998
1998-12-28
Active Biotech forvärvar 100 % i Transport AB Movera
1998-12-22
Active Biotech säljer sin fastighet i Lund for 320 mkr med en realisationsvinst på 80 mkr
1998-12-16
Sven Andréasson ny VD i Active Biotech
1998-11-19
Delårsrapport 1 januari - 30 september 1998
1998-11-17
BioPhausia och Active Biotech i samarbete om cancerprojekt.
1998-09-07
FLAGGNINGSMEDDELANDE
1998-07-02
Mycket stor anslutning till Active Biotechs personaloptioner
1998-06-29
Active Biotech ökar satsningen på ETEC- och koleravaccin genom förvärv av Vitec
1998-06-05
Active Biotech ABs riktade nyemission fulltecknad
1998-05-20
Nyemissionen fulltecknad
1998-04-17
Active Biotechs bolagsstämma godkände förvärvet av Lund Research Center
1998-04-02
Active Biotech renodlar - säljer Rederi AB Heron. Soliditeten ökar från 34% till 49%.
1998-03-31
Nyemissioner i Active Biotech
1998-03-10
Ny forskningschef i Active Biotech
1998-03-09
Active Biotech ny kraft inom bioteknik
1998-02-26
Bokslutskommuniké för 1997
Annual General Meeting - May 15, 2013
Annual Report 2012
Subscribe to press releases from Active Biotech
Read more >>